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ABSTRACT
This study aimed to research the post-treatment quality of life (QOL) between radiotherapy (RT)- and operation
(OP)-treated early cervical cancer survivors, using separate questionnaires for physicians and patients. We adminis-
tered an observational questionnaire to patients aged 20–70 years old with Stages IB1–IIB cervical cancer who had
undergone RT or OP and without recurrence as outpatients for ≥6 months after treatment. We divided 100 registered
patients equally into two treatment groups (n = 50 each). The average age was 53 and 44 years in the RT and OP
groups, respectively. The RT group included 34 and 66% Stage I and II patients, respectively, whereas the OP group
included 66 and 34% Stage I and II patients, respectively. The OP group included 58% of patients with postoperative
RT. Combination chemotherapy was performed in 84 and 48% of patients in the RT and OP groups, respectively. On
the physicians’ questionnaire, we observed significant differences in bone marrow suppression (RT) and leg edema
(OP). On the patients’ questionnaire, significantly more patients had dysuria and leg edema in the OP group than
in the RT group, and severe (Score 4–5) leg edema was significantly higher in the post-operative RT group than in
the OP only group. The frequency of sexual intercourse decreased after treatment in both groups. On the patients’
questionnaire, there were no significant differences between the two groups regarding sexual activity. These findings
are useful to patients and physicians for shared decision-making in treatment choices. The guidance of everyday life
and health information including sexual life after treatment is important.
Keywords: uterine cervical cancer; radiotherapy; surgery; quality of life; questionnaire; sexuality
INTRODUCTION
Radiotherapy (RT) results at early-stage uterine cervical cancer are
comparable to those of surgery [1]. However, in Japan, surgery-
preferring gynecologists are responsible for determining treatment
policies, therefore, most patients with stages IB–IIB cervical can-
cer were indicated for radical hysterectomy (RH) until recently.
Conversely, because the National Cancer Institute (NCI) alert [2]
recommends concurrent chemoradiation therapy [CCRT] for locally
advanced cervical cancer, patients with stages IB2–IIB disease who
were previously indicated for surgery are also increasly indicated for
CCRT in Japan [3]. In the 2016 annual report of the Committee
on Gynecologic Oncology, ∼90% (3737/4164) of patients with
stage I disease (18% [659/3737] received postoperative RT) and
47% (846/1804) with stage II disease (50% [420/846] received
postoperative RT) underwent surgery, and only 9% (386/4164) and
52% (934/1804) of patients with stage I and II disease received radical
RT, respectively [3]. From 1975 to 2000, the age of cervical cancer
patients peaked at >75 years; however, from 2004, it peaked in an
earlier bracket at 35–44 years, indicating that the incidence of cervical
cancer is increasing among young Japanese women [4].
Posttreatment quality of life (QOL) is an important factor to con-
sider before patients undergo treatment for uterine cervical cancer.
Those with early cervical cancer have more than one treatment option;
it is thus important that they understand the post-treatment change
in QOL for each modality. Although the change in QOL after treat-
ment is one of the crucial deciding factors in treatment selection,
relevant information is limited because very few studies on this issue
have been conducted in Japan [5, 6]. The long-term survival of young
patients with cervical cancer highlights the importance of the late
adverse events of treatment, particularly considering the increasing
number of younger patients [2]. It is important to survey long-term
survivors to understand the real-world situation with respect to adverse
events associated with treatment and to determine the effects of dif-
ferent treatment approaches on QOL. Thus, the aim of the present
study was to evaluate the incidence of adverse events and compare the
differences in QOL between cervical cancer patients who underwent
RT and radical operation (OP). These findings might help patients in
the selection of treatment modalities. We present a multi-institutional
study conducted by the Japanese Radiation Oncology Study Group
( JROSG) gynecologic cancer committee.
MATERIALS AND METHODS
Patients
The present study was approved by the Institutional Review Boards
(IRB) of all 12 institutions that participated in this study. The inclu-
sion criteria were: (i) histologically confirmed FIGO Stages IB1–IIB
cervical carcinoma; (ii) radical RT (combined external RT with intra-
cavitary brachytherapy) or RH with or without postoperative RT: with
or without chemotherapy; (iii) age = 20–70 years; (iv) recurrence-free;
(v) final treatment was 6 months prior; (vi) performance status (PS)
score of 0 or 1; (vii) could read and understand the questionnaire; (viii)
no serious organ dysfunction and no psychological disease; and (ix)
provision of written informed consent. The exclusion criteria were: (i)
cervical stump cancer; (ii) use of conization or laser ablation technique
and any other surgery except for RH; (iii) active double cancer patients
who were treated and did not develop a recurrence within 5 years of
treatment completion; and (iv) were judged unsuitable for inclusion
in the study by a physician. We considered that PS ≤ 1 (0 or 1) is
appropriate for comparing the RT group with the OP group because
we sometimes encounter patients with PS ≥2 in the RT group, on the
other hand surgery is usually difficult for patients with PS ≥2. The
planned number of patients required for this study was 50 patients each
in the RT and OP groups, total 100 patients.
At each institution, consecutive patients who met the eligibility cri-
teria and obtained consent from the physician were enrolled between
the January 2012 and April 2014. Patients in the OP group had under-
gone surgery between 22 August 1990 and 25 September 2009, and
patients in the RT group had undergone radiotherapy between 12
December 1998 and 12 November 2008.
We conducted the questionnaire survey only once. The timing of
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evaluation, how the patient’s quality of life has changed is unknown
except for items of dysuria described below from patients’ question-
naires.
Patient recruitment
The recruitment procedure for this study varied by institution: in
some institutions, the radiation oncologists asked the gynecologists to
recruit all OP patients, while in others if the patients received post-
operative RT the radiation oncologists were in charge of patient recruit-
ment. The 21 patients who were treated with surgery alone without
post-operative RT in the OP group were directly recruited by gynecolo-
gists (14 patients from 4 institutions), or referred by gynecologist to the
outpatient department of radiation therapy, or the radiation oncologist
went to the outpatient department of gynecology to recruit the patient
(7 patients from 2 institutions). Radiation oncologists alone recruited
and assessed both RT patients and OP patients in 7 institutions (in
one institution only RT patients were recruited), of which in 6 institu-
tions, radiation oncologists also recruited and assessed postoperative
RT patients. In 3 institutions, patient recruitment was a joint effort
between the radiation oncologists and gynecologists In 1 institution,
radiation oncologist referred to the gynecologist for both recruitment
and assessment of RT and OP patients. No patient was recruited in 1
institution. Hence, patients were recruited jointly by radiation oncolo-
gists and gynecologists in 4 institutions.
Overall 21 physicians including 14 radiation oncologists and 7
gynecologists cooperated in recruiting the patients and filling out the
questionnaires. A total of 78 patients were recruited by radiation oncol-
ogists and 22 were recruited by gynecologists. Of the 50 RT patients, 49
were recruited by radiation oncologists and 1 patient was recruited by a
gynecologist, and in the 50 OP patients, 29 were recruited by radiation
oncologists and 21 by gynecologists.
Overall, 55 patients were recruited by the same physicians (23 RT
patients and 32 OP patients), of which 49 patients (22 RT patients
and 27 OP patients) were recruited by 5 radiation oncologists and the
rest (1 RT, 5 OP) by a gynecologist. Of the remaining 45 patients, 29
patients (27 RT patients, 2 OP patients) were recruited by 8 radiation
oncologists and the other 16 patients (OP patients only) by 6 gynecol-
ogists.
QOL assessment
We assessed the patients’ QOL using The European Organization for
Research and Treatment of Cancer (EORTC) Quality-of-Life ques-
tionnaire (QLQ)–Cervical Cancer Module (CX24) [7]. We obtained
permission from the EORTC to translate and validate the QLQ –CX 24
for use in the Japanese population. Concurrently, while preparing the
Japanese version of the QLQ –CX 24, our working group considered
original questionnaires based on the literature, guidelines and clinical
experience to ensure that the QOL was evaluated according to actual
clinical practice in Japan.
We found that questions on treatment-specific adverse events and
sexual life were not identified in the preparation of the Japanese version
of EORTC QLQ –CX 24. Thus, we agreed to develop a questionnaire
consistent with Japanese culture and lifestyle as follows.
We asked the patients about their surgical wound, included diarrhea
and constipation as separate questions, and added a question regarding
hematuria as a late adverse event of RT. Since dysuria may change
immediately after treatment and over time, we asked for the most severe
symptom immediately after treatment and then whether it improved.
We evaluated abdominal pain using five grades: (i) slight pain; (ii)
light pain; (iii) moderate pain; (iv) strong pain; (v) very intense pain,
because it was subjective to each patient. With respect to sexual life, we
asked whether the patients had a partner (Q21). In the EORTC QLQ –
CX 24, sexual life during the past 4 weeks post-treatment is assessed;
however, because Japanese sexual life is generally considered to be less
active than that of the Westerners [8], we set this period at 1 year. We
added a question on bleeding in addition to pain as a possible con-
cern during sexual intercourse (Q23). Regarding the changes in sexual
activity after treatment (Q32–45), we referred to a study by Sakurai
et al. [9]. Finally, we created a 45-item QOL questionnaire for the
present study (Table 1). A Japanese version of this QOL questionnaire
is attached as Supplementary Table 1, see online supplementary mate-
rial. We explained the background of the questionnaire development to
the EORTC and obtained permission to use our modified version. The
EORTC translation team leader instructed us to state that we referred
to Greimel et al.’s paper [7]. A Japanese QOL questionnaire has been
developed previously [10].
Our patients completed the Japanese version questionnaires in a
private room and in compliance with the Japan Council for Quality
Health Care standards.
Collection of clinical information
The physicians confirmed that the patients met all the selection criteria
and obtained written consent forms from each patient. The question-
naire we created for this study included 104 questions for physicians to
collect information on (i) patient characteristics, (ii) treatment meth-
ods (radiation therapy, surgery, postoperative radiotherapy, combina-
tion chemotherapy), (iii) recurrences, (iv) adverse events, and (v)
medical advice on their sexual life (Table 2). The Japanese version of
this physicians’ questionnaire is provided as Supplementary Table 2,
see online supplementary mateial.
The physicians who participated in the study were 11 males and 10
females.
After-treatment medical guidance on patients sexual
activity by healthcare professionals
We confirmed whether the physician or a nurse provided guidance to
the patients about sexual activity after the treatment of cervical cancer
at each institution.
Statistical analysis
We performed t-tests or Wilcoxon’s rank sum tests to compare con-
tinuous variables, and χ 2-tests or Fisher’s exact tests were performed
to compare categorical variables. We conducted a univariate analy-
sis using χ 2-tests or Fisher’s exact tests and a multivariate logistic
regression analysis using a stepwise selection method to identify the
factors associated with adverse events (14 variables) and QOL (45
variables) depending on the treatment technique (RT and OP). Factors
that reached the 0.25 level of significance by stepwise procedure were
included in the multivariate logistic regression analysis. All data were
analyzed using JMP version 9 software (SAS Institute, Cary, NC, USA).
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A total of 100 patients were registered from January 2012 to April 2014,
with 50 patients each in the RT and the OP group (Table 3). There was
no difference in the survey time from the treatment between the two
groups (P = 0.346). In the RT group there were respectively 34 and 66%
of patients with Stage I and II, while in OP group we had respectively
66 and 34. There were more stage I tumors in the OP group than in the
RT group, and more stage II tumors in the RT group than in the OP
group (P = 0.001). The patients in the OP group were younger than
those in the RT group (P < 0.001). We have not investigated the body
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Table 3. Patients’ characteristics and treatment methods
RT (n = 50) OP (n = 50) P –value
Age at treatment, yearsa 53 ± 12 (26–70) 44 ± 10 (26–67) <0.001
Age at investigation, yearsa 56 ± 13 (27–76) 48 ± 10 (30–69) 0.001
Years from treatment, yearsa 3.2 ± 2.5 3.8 ± 3.7 0.346
Stage I 17 (34%) 33 (66%)
II 33 (66%) 17 (34%) 0.001
Maximum tumor diameter (cm)a,∗ 4.4 ± 1.04 3.4 ± 1.25 0.004
Pelvic lymph nodes metastasis ≥1 cm
Yes 19 (38%) 9 (18%)
No 31 (62%) 41 (82%) 0.026
PS 0 43 (86%) 46 (92%)
1 7 (14%) 4 (8%) NSe
Coexisting illnessb
Yes 9 (18%) 5 (10%)
No 41 (82%) 45 (90%) NS
Previous abdominal surgeryc
Yes 3(6%) 3(6%)
No 47 (94%) 47(94%) NS
Marriage historyd
Yes 47 (94%) 46 (92%)
No 3 (6%) 4 (8%)
Delivery history
Yes 36 (73%) 44 (92%) 0.018
No 13 (27%) 4 (8%)
Number of deliveries 2 (0–3) 2 (0–4)
Postoperative RT (PO-RT) — 29 (58%)
PO-RT alone — 11 (22%)
PO-RT + chemotherapy — 18 (36%)
Surgery alone — 14 (28%)
Surgery + chemotherapy — 7 (14%)
Combination of chemotherapy 42 (84%) 25 (50%) <0.001
aMeans and standard deviations, otherwise numbers and proportions.
bE.g. diabetes mellitus, hypertension.
cE.g. appendectomy.
dIncluding common-law marriage.
eNS = not significant.
Treatment
The RT group received a combination of external beam RT (EBRT)
to the pelvic cavity and high dose rate intracavitary brachytherapy
(HDR-ICBT). EBRT and HDR-ICBT were administered in accor-
dance with the guidelines for RT included in General Rules for Clinical
and Pathological Study of Uterine Cervical Cancer in Japan [11]. In the
early part of EBRT, the median 30.4 Gy was delivered to the whole
pelvis. Thereafter, the remaining the median 20 Gy was administered
to the same whole-pelvic field with central shield. EBRT was given
using the four-field box technique with 3D conformal radiation therapy
(3D-CRT) for 37 patients (74%), and the parallel-opposed (antero-
posterior–posteroanterior) technique for the other 13 patients (26%).
Intensity modulated radiation therapy (IMRT) was not used. Eleven
(22%) patients received boost irradiation with mean dose of 6.8 Gy,
while 6 (12%) patients received extended field irradiation with whole
pelvis and para-aortic region. The median number of HDR-ICBT frac-
tions was 4, and the median dose at Point A/fraction was 6 Gy. The
mean overall treatment time was 47.3 days. In 42 (84%) patients who
received combined chemotherapy, cisplatin (CDDP) was used in 40
cases, mitomycin C in 6 cases and nedaplatin in 2 cases.
All of the patients in the OP group underwent RH, pelvic
lymphadenectomy and bilateral salpingo-oophorectomy. The number
of dissected pelvic lymph nodes was 7–120 (mean 38), and the
number of metastatic pelvic lymph nodes was 0–20 (mean 1.08).
One or both ovaries were preserved in 6 (12%) patients; all patients
were in stage IB, and the mean patient age was 35 years (range,
27–48 years). In total, 29 (58%) patients received postoperative
RT, 18 of whom also received chemotherapy. Of the 18 patients
who received postoperative RT and chemotherapy, 5 received the
neo-adjuvant chemotherapy (NAC) → OP→postoperative RT
regimen and 13 received the OP→postoperative CCRT regimen.
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Univariate analysis Multivariate analysis
ORa 95% CI P-value AOR 95% CI P-value
BM suppression 39 21 0.2 0.1–0.5 <0.001 0.3 0.1–0.7 0.012
Diarrhea 36 23 0.3 0.1–0.8 0.008 0.4 0.1–1.1 0.064
Cystitis 9 6 0.6 0.2–1.9 0.400
Dysuria 0 17 − <0.001
Constipation 0 4 − 0.041
Pelvic lymphocele 0 4 − 0.041
Hot flush/sweating 2 10 6.0 1.2–29.0 0.014 3.7 0.6–21.2 0.147
Rectum 4 1 0.2 0.03–2.2 0.169 0.0 0.01–1.26 0.073
Bladder 4 1 0.2 0.03–2.2 0.169
Small intestine 3 3 1.0 0.2–5.2 1.000
Large intestine 1 1 1.0 0.1–16.4 1.000
Leg edema 1 15 4.9 1.5–16.2 0.005 6.4 1.7–24.0 0.006
Bone 2 1 0.5 0.04–5.6 0.558
aOR = odds ratio (side effect occurred easily in the OP group if >1, and in the RT group if <1), AOR = adjusted odds ratio, CI = confidence interval, BM = bone marrow.
patients received surgery + chemotherapy (2 patients received NAC,
4 received adjuvant chemotherapy and 1 received NAC and adjuvant
chemotherapy). Of the 25 (50%) patients who were treated with
combined chemotherapy, 12 were treated with CDDP. (Table 3).
Adverse events according to the physicians’
questionnaire
The RTOG/EORTC classification lists the acute and late adverse
events for RT patients, which do not apply to patients who have
undergone surgery. So, we used the CTCAE classification to describe
the late adverse events in OP patients.
Based on the physicians’ questionnaire, there were significantly
more cases of bone marrow suppression (BMS) and diarrhea in the RT
group than in the OP group as per the univariate analysis, and there
were significantly more cases of BMS in the RT group than in the OP
group in multivariate analysis (P = 0.013). On the other hand, there
were significantly more cases of dysuria, leg edema, hot flush/sweating,
constipation and pelvic lymphocele in the OP group than in the RT
group in univariate analysis, and leg edema was significantly more
common in the OP group than in the RT group in multivariate analysis
(P = 0.006) (Table 4). In Table 4, all patients were evaluated for any
adverse events other than urinary stenosis, which was not seen in any
patient in the RT or OP group.
Self-reported QOL according to the patients’
questionnaire
In total, 92% (92/100) of patients responded to the questionnaire
(94% [47/50] and 90% [45/50] of patients in the RT and OP groups,
respectively). As the questions were printed on both sides of the paper,
some patients did not complete the form because they may have not
noticed the back side.
In terms of subjective symptoms, there were significantly more
patients with dysuria, constipation, leg edema, lower abdominal edema
and hot flushes/sweating in the OP group than in the RT group in
univariate analysis. In multivariate analysis, there were significantly
more patients with leg edema and dysuria in the OP than in the RT
group (Table 4).
Dysuria and subsequent changes
Based on the physicians’ questionnaire, no cases of dysuria were
reported in the RT group, while 34% of patients in the OP group
experienced dysuria (Table 4, 0% [0/50] vs 34% [17/50], univariate
analysis, P < 0.001). Based on the patients’ questionnaire, significantly
more patients complained of dysuria in the OP group (44% [22/50])
than in the RT group (8.5% [4/47]) (Table 5, multivariate analysis,
P = 0.022). Further, based on the responses provided in the patients’
questionnaire, patients who developed dysuria sometimes, quite a bit,
or very much, in either group, improved quite a bit, almost fully, or
completely recovered, in 68% (15/22: OP) and 50% (2/4: RT) of
cases, with no significant differences between the patients in the OP or
RT groups.
On the other hand, postoperative dysuria was significantly more
prevalent in patients in the postoperative RT group (48.3% [14/29])
than in patients in the OP alone group (14.3% [3/21]) (P = 0.009)
based on the responses collected from the physicians’ questionnaire,
while postoperative dysuria was not significantly different between the
two groups (postoperative RT group (44.8% [13/29]) vs OP alone
group (42.9% [9/21]) (P = 0.890)) based on the responses provided
in the patient’ questionnaire.
Leg edema in the OP group
Assessment of leg edema differs between the physician and the patient.
As assessed by the physician, postoperative RT was not associated
with a severe risk of leg edema (P = 0.123: Fig. 1a). However in the
patients’ questionnaire, irreversible severe (Score 4–5) leg edema was
significantly more observed in the postoperative RT group than in the
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Table 5. Univariate and multivariate analysis of variable factors between the radiotherapy and operation group on the patients’
questionnaire
Univariate analysis Multivariate analysis
Scale Y/Na RT OP ORd 95% CI P-value AOR 95% CI P-value
Clinical symptoms
Genitourinary symptoms
Difficulty emptying the bladder Y/N 4/43 22/28 8.4 2.6–27.1 < 0.001 4.6 1.3–19.1 0.022
Leaking of urine Y/N 7/41 14/36 2.3 0.8–6.3 0.106 1.0 0.3–4.0 0.975
Pain when urinating Y/N 4/46 1/48 0.2 0.02–2.2 0.176
Increased frequency of urination Y/N 12/38 8/39 0.6 0.2–1.77 0.396
Hematuria Y/N 2/48 2/46 1.0 0.1–7.7 0.967
Vaginal discharge Y/N 8/42 4/45 0.5 0.1–1.7 0.232
Vaginal hemorrhage Y/N 1/49 0/49 0.0 0.320
Gastrointestinal symptoms
Diarrhea Y/N 17/33 18/30 1.6 0.5–2.7 0.718 0.6 0.2–2.0 0.446
Constipation Y/N 15/35 25/24 2.4 1.1–5.5 0.033
Blood in stools Y/N 1/49 1/48 1.0 0.06–16.8 0.989
Pain
Lumbago Y/N 14/36 15/34 1.0 0.4–2.7 0.775
Pain of the inguinal region Y/N 11/38 19/30 2.2 0.9–5.3 0.795
Lower abdominal pain Y/N 7/43 11/38 1.8 0.6–5.0 0.276 1.3 0.3–4.9 0.717
Leg or lower abdominal lymphedema
Swelling in one or both legs Y/N 3/47 17/32 8.3 2.3–30.8 <0.001 4.9 1.2–25.2 0.033
Lower abdominal edema Y/N 1/40 9/40 11.0 1.3–90.7 0.007
Peripheral neuropathy
Tingling or numbness in feet Y/N 9/39 11/38 1.3 0.5–3.4 0.653
Menopausal symptoms
Hot flushes and/or sweats Y/N 10/37 19/26 2.7 1.1–6.8 0.031
Body image after suffering from a
cancer
Feel less feminine as a result of disease
or treatment
Y/N 7/39 8/37 1.2 0.4–3.7 0.742
Sexual partner existence Y/N 30/14 38/7 2.5 0.9–7.0 0.071
Sexual vaginal functioning
Vaginal dryness during sexual activity Y/N 5/8 8/17 0.7 0.2–3.0 0.690
Vaginal shortness Y/N 1/12 6/19 3.8 0.4–35.5 0.219
Vaginal tightness Y/N 2/11 6/19 1.7 0.3–10.1 0.537
Pain during sexual intercourse Y/N 6/8 8/17 0.6 0.2–2.4 0.498
Sexual worry
Worry about pain during sexual
intercourse
Y/N 10/27 15/28 1.4 0.6–3.8 0.450
Worry about post-coital genital
bleeding
Y/N 6/31 11/33 1.8 0.6–5.2 0.334
Sexual activity, enjoyment and
change
Enjoying sexual activity N/Y 9/2 20/4 1.1 0.2–10 0.912
Using something during sexual
intercourse
Y/N 2/11 8/16 2.8 0.5–15.5 0.241
Frequency of sex before the
treatmentb
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Table 5. Continue
Univariate analysis Multivariate analysis
Scale Y/Na RT OP ORd 95% CI P-value AOR 95% CI P-value
Frequency of sex after the treatmentb Y/N 2/33 8/38 3.5 0.7–17.5 0.114
The time you started having sex after
treatmenctc
Y/N 7/26 17/27 2.3 0.8–6.6 0.102
No change in the feelings and/or the
condition of the body
Y/N 26/6 33/11 0.7 0.2–2.1 0.519
I did not gradually do sex because of
my feeling and age
Y/N 22/3 30/11 0.4 0.09–1.5 0.372
I did not gradually do sex because of
partner’s feeling and age
Y/N 20/4 30/12 0.5 0.1–1.8 0.278
Because my physical condition is not
good, I do not bring myself to do sex
Y/N 9/15 20/23 1.4 0.5–4.0 0.475
Hate sexual intercourse as a result of
cervical cancer.
Y/N 13/11 23/18 1.1 0.4–3.0 0.880
I became more interested in sexual
intercourse than previously
Y/N 4/20 7/36 1.0 0.3–3.7 0.967
Partner declines or hates sexual
intercourse after my treatment
Y/N 9/13 20/20 1.4 0.5–4.1 0.492
Partner became more interested in
having sexual intercourse
Y/N 4/17 6/34 0.8 0.2–3.0 0.685
I do not want to have sexual
inter-course, but I endure it for my
partner
Y/N 6/10 14/29 0.8 0.2–2.7 0.721
After treatment, insertion became
difficult
Y/N 9/10 17/20 0.9 0.3–2.9 0.920
No pleasant feeling at the time of
sexual intercourse
Y/N 11/8 20/16 0.9 0.3–2.8 0.868
aY/N: Yes/No.
bClassified as Yes/No. Frequency greater than once a month: Yes (Y); frequency, less than once a month: No (N).
cUnder 1 year: Y; interval of more than 1 year or never: N.
dOR = odds ratio (side effect occurred easily in the OP group if >1, and in the RT group if <1), CI = confidence interval, AOR = adjusted odds ratio.
was a discrepancy between the physicians’ evaluation and the patient-
reported outcome.
Change in sexual activity
In total, 88% of the patients answered detailed questions on sexual
activity (Q32–45). There were no significant differences in sexual
activity between the RT and the OP groups (Table 4). In total, 85%
(85/100) of the patients responded to the question regarding the
frequency and start time of sexual intercourse (Q32–34). Of these,
62% (53/85: RT, 52% [20/38]; OP, 70% [33/47]) were engaged in
sexual activity within the past 1 year before treatment, while only 39%
(33/85: RT, 26% [10/38]; OP, 47% [22/47]) were engaged in sexual
activity within 1 year after treatment. This showed that the frequency
of sexual intercourse at 1 year after treatment decreased significantly as
compared to 1 year before treatment in both groups (overall: P = 0.001;
RT group: P = 0.019; OP group: P = 0.021, Fig. 2).
Medical guidance for patients regarding sexual activity
Following treatment, only 31% (31/100) of all patients received med-
ical guidance from a physician or nurse. These included: 24% (12/50)
and 38% (19/50) in the RT and the OP groups, respectively. Physicians
or nurses provided direct guidance on sexual life to 4 and 17 patients
in the RT and OP groups, respectively. Of the 21 physicians who
participated in this study, 11 were males and 10 were females. How-
ever, the physician who filled out the questionnaire and the physician
who gave the guidance regarding sexual intercourse after treatment
to the patient were different for the OP alone group. For this reason,
we researched the gender of the physicians who gave sexual advice.
As shown in Table 2, the guidance items regarding sexual intercourse
from medical staff to patients is: 1. Instructed, 2. Not instructed, 3.
Pamphlet, 4. Others. We considered responses that were 1, 3, or 4
as instructed. Guidance rates for male doctors was 28.6% (18/63)
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Fig. 1. Degree of leg edema in those complaining of leg edema according to the presence or absence of postoperative RT (PO-RT)
in the OP group on (a) the physicians’ and (b) the patients’ questionnaire. ∗ One patient with PO-RT did not answer the question.
Y: yes, N: no. Score1∗∗, not at all; 2, a little; 3, sometimes; 4, almost always; 5, always.
Fig. 2. Change in frequency of sexual activity 1 year before or after (a) radiotherapy or (b) operation in patients with uterine
cervical cancer.
relationship between providing sexual activity guidance and the gender
of the physician.
DISCUSSION
Given the difference in treatment policies for RT and the surgical
methods for uterine cervical cancer between Western countries and
Japan, the post-RT or post-surgery QOL in Japan should be compared
cautiously with that of Western countries.
In this study, we found significant differences in BMS in the RT
group and leg edema in the OP group as assessed according to the
physicians’ questionnaire. This finding was attributed to the signifi-
cantly higher rate of combined chemotherapy in the RT group than in
the OP group.
Postoperative lymphedema of the legs is a considerable problem
due to RH, which includes complete pelvic lymph node dissection
[12]. Many studies reported postoperative lymphedema of the legs
[12–19], with the rate of lymphedema being higher in patients treated
with OP and RT combined than in those treated with OP alone [19].
Further, one study reported that although emotional distress and QOL
issues improved during the first 2 years after cervical cancer diagnosis,
lymphedema and menopausal symptoms persisted [17]. In our study,
leg edema was significantly more common in the OP group than in
the RT group, according to both the physicians’ and the patients’
questionnaires. Meanwhile, the physician’s questionnaire showed no
significant difference in the severity of postoperative lymphedema of
the leg between the post-operative RT group and the OP only group.
However, based on the patients’ subjective symptoms self-assessment,
the degree of lymphedema of the leg in the OP group was significantly
higher in patients with post-operative RT than that in the OP only
group (Fig. 1).
In line with a previous study, we also observed a large gap between
the patients’ subjective assessment of symptoms and physicians’ objec-
tive evaluation of lymphedema [5]. Despite the physicians’ assurance
that the leg edema would cause minimal discomfort, most patients tend
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daily living. Therefore, the self-reported patients’ QOL questionnaires
in our study were considered very important.
Bladder, ano-rectal and sexual complications are common follow-
ing RH for cervical cancer. In general, the incidence of temporary
voiding dysfunction is higher following RH, while the incidence of
urine storage dysfunction is higher following CCRT [20–22].
The major adverse event following RH for invasive cancer of
the cervix is postoperative bladder dysfunction. Bladder dysfunction
is a direct result of injury to the sensory and motor nerve supply
to the detrusor muscle of the bladder [13]. Post-operative RT was
associated with significantly more contracted and unstable bladder
[13]. Butler-Manuel et al. compared QOL before and after OP and
reported that urinary incontinence, particularly of urge incontinence,
and voiding difficulties as well as tenesmus increased significantly after
OP (P < 0.05 and P < 0.05, respectively) [20]. Like the findings of
Katepratoom et al. [21], the incidence of difficulty in bladder emptying
was significantly higher after OP as compared to RT in our study
by both physicians’ (P < 0.001: univariate analysis) and patients’
(P = 0.022: multivariate analysis) questionnaires. In our study, the
incidence of post-operative dysuria in the post-operative RT group was
higher than in the OP alone group in the physicians’ questionnaire,
but there was no difference between the two groups in the patients’
questionnaire. This was the opposite difference in assessment between
physicians’ questionnaire and patients’ questionnaire to that for
leg edema.
Rectal bleeding is a late adverse effect of RT [23,24]. Chronic
adverse effects of intestinal RT can cause telangiectasis of the rectum
and changes to the blood vessels of the rectal tissues [23]. However,
we found no significant difference in rectal bleeding between the RT
and OP groups in both the physicians’ (RT group: 8% [4/50], OP
group: 2% [1/50], P = 0.073: multivariate analysis) and the patients’
(RT group: 2.0% [1/49], OP group: 2.1% [1/48], P = 0.989: univariate
analysis) questionnaire in our study (Table 4 and 5). Diarrhea is a
chronic symptom after RT [22, 25]. In our study, univariate analysis
of the physicians’ questionnaire showed that diarrhea was significantly
more frequent in the RT group (RT group: 72% [36/50], OP group:
46% [23/50], P = 0.008); however, there was no significant differ-
ence between the two groups as per the patients’ questionnaire (RT
group: 39.4% [13/33], OP group: 60% [18/30], P = 0. 718). Hu et al.
reported only minor differences in long-term QOL at least 2 years
post-treatment between OP and RT patients, where pelvic neural dys-
function was significantly higher in the OP group, while intestinal
dysfunction was higher in the RT group [24].
As sexual life differs between Japanese and Western people, a simple
comparison is difficult. Japanese people are generally more reluctant
to perform sexual activity [8] as compared to Westerners. Despite
this, various reports have investigated post-treatment sexual activity in
uterine cervical cancer patients. These reports show varying patterns of
deterioration, compromise and improvement in sexual activity before
and after various treatment modalities. Some authors have reported
that cervical cancer survivors treated with RT had worse sexual func-
tion than the control group and those treated with RH and lymph node
dissection [12, 18, 25–29]. Irradiated women faced more difficulty in
becoming sexually aroused, attaining vaginal lubrication and achieving
sexual satisfaction, and experienced significantly more pain during
intercourse than those in the RH or control group [18, 30]. Meanwhile,
Butler-Manuel et al. reported that 55% of patients considered that their
sex life was worse after the surgery and 13% ceased having sexual
activity [20]. Chronic fibrotic changes in pelvic tissue after RT create
vaginal atrophy, which leads to persistent sexual and vaginal problems,
such as dyspareunia and a lack of lubrication in cervical cancer patients
[18, 27, 29]. These problems compromised their sexual activity and
satisfaction. On the other hand, early diagnosis and treatment could
facilitate a gradual return to a normal life and even an improvement in
sexual activity in both those who undergo OP and CCRT + OP [16].
Compared to surgery alone, intracavitary RT, external RT, or both,
in addition to or instead of surgery, had a small effect on the risk of
reduced vaginal lubrication, shortness or inelasticity [31]. Kobayashi
et al. [6] reported no significant differences in anxiety and depression
scores among the three treatment modalities (RT, CCRT and OP
+ RT).
With respect to sexual activity, we found no statistically significant
differences between the RT and OP groups based on the patients’
questionnaire. However, the frequency of sexual activity in both groups
also decreased significantly after treatment as compared to before treat-
ment, which was consistent with other reports [18,20].
In our study, only 31% of all patients (RT: 24%; OP: 38%) received
guidance about post-treatment sexual activity from the medical staff;
this low rate was attributed to busy outpatient clinics and lack of profes-
sional knowledge on sexual activities. Guidance rates of male doctors
was 28.6% (18/63) and that of female doctors was 35.1% (13/37)
(P = 0.493). There was no relationship between providing sexual activ-
ity guidance and the gender of the physician. Physicians are generally
focused on monitoring relapse and late adverse events and do not have
adequate time for consultations on the patients’ sexuality. Although
sexuality is an important element of QOL, in Japan, there is insufficient
support from healthcare workers on discussing sexuality. Further, it is
difficult for patients to consult healthcare workers regarding sex [32].
Sexuality-related information in the context of adverse events after
treatment should be provided to all patients, regardless of age or type
of treatment [33]. Educating the medical staff on patient sexuality,
providing information to patients and establishing a consultation desk
is needed.
One of the causes of pain during sexual intercourse or during pelvic
examination is dryness, vaginal adhesion due to RT and ovarian deficit
symptoms due to oophorectomy. Vaginal pain can be improved by use
of a vaginal dilator to prevent adhesion after RT or with jelly or mousse
[34]. Preventing vaginal adhesion may lead to the early detection of
cervical recurrence. The proportion of patients using a dilator after the
initiation of RT was reported to decrease with time [35]. Training the
medical support staff is also important. Books, pamphlets and lectures
can be given to patients, partners and physicians to effectively provide
more information on sexuality [32].
Our study has several limitations. First, this observational ques-
tionnaire survey study was not a prospective survey, and was con-
ducted only once. However, there was no difference between the two
groups with regard to the timing of the survey, so we evaluate that it
is meaningful, even once. Second, since the questions were designed
for a small number of patients in Japan, detailed analysis of every
item was limited in between-group comparison. Third, post-operative
irradiation was performed in 58% of the surgery group in this study.
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radiation oncologists, which was more than the 33% (7/21) of gyne-
cologists, in this study more postoperative RT patients seemed to be
recruited. Therefore, if we compare RT and OP alone, it seems to be
biased. Fourth, the original QOL questionnaire used for this survey
was developed by us. This QOL questionnaire, comprising a total of
45 items with disease-specific questions based on clinical practice in
Japan, has not yet been validated. However, it is also being referenced
in an ongoing Japanese clinical trial ( JGOG1082). The usefulness of
this QOL questionnaire should be further validated in prospective
large-scale studies from now on. Future research requires a prospective
design with long-term follow-up of QOL after treatment. To further
develop our research, we are planning to release a pamphlet about the
treatment of uterine cervical cancer.
CONCLUSION
Post-treatment QOL change of RT and OP patients with early-
stage cervical cancer were each characterized. Our findings will
assist patients and physicians shared decision-making with respect
to treatment choice. Healthcare professionals should provide patients
with more guidance about coping with post-treatment changes in their
QOL, including sexual life, irrespective of whether they undergo RT
or OP.
SUPPLEMENTARY DATA
Supplementary data is available at RADRES Journal online.
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